Research Studies
Back to Results
A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies
Primary Objective
Determine the safety and tolerability of VRx-3996/valganciclovir. Evaluate the impact of parameters of HIV infection (e.g., CD4 cell counts, HIVqPCR) on safety and efficacy. And Evaluate the impact of VRx-3996/valganciclovir on replication of non-Alpha herpesviruses.
Details
Age
Adult
Type of Study
Treatment
Locations
Lone Tree Medical Center
University of Colorado Hospital
Principal Investigator
Brad Haverkos, MD
Study ID
Protocol Number: 17-2074
More information available at ClinicalTrials.gov: NCT03397706
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers